There has been significant debate in the surgical and medical communities regarding the appropriateness of using aspirin alone for venous thromboembolism (VTE) prophylaxis following total knee arthroplasty (TKA).
I n 2015, an estimated 719 000 total knee arthroplasties (TKA) were performed in the United States. 1 A significant associated risk is venous thromboembolism (VTE), including fatal pulmonary embolus (PE). In an early report of cases performed from 1974 to 1979, the incidence of symptomatic PE was 1.7%. 2 Anticoagulation has been recommended since. Both the American College of Chest Physicians and the American Association of Orthopaedic Surgeons (AAOS) recommended the use of pharmacologic VTE prophylaxis. 3, 4 The American College of Chest Physicians favored low-molecular-weight heparin (LMWH), while the AAOS felt that there was insufficient evidence for a specific recommendation. Studies, such as the Pulmonary Embolism Prevention trial, 5 found a significant reduction in VTE events in patients with hip fracture receiving aspirin, but significance was not reached in patients undergoing elective hip or knee arthroplasty. Additionally, the Pulmonary Embolism Prevention trial was not designed to answer whether aspirin alone could replace anticoagulants for VTE prophylaxis.
A systematic review and meta-analysis 6 of aspirin as prophylaxis after TKA concluded that most studies were of low quality, and numerous studies comparing prophylaxis include cases with asymptomatic deep venous thromboembolism. [6] [7] [8] Constructing randomized clinical trials comparing different prophylactic strategies has been difficult, given the overall low incidence of VTE events. 9, 10 Additionally, many studies underrepresented the risks of surgical site bleeding and reoperation after TKA. 11, 12 There are concerns of potential publication bias in favor of anticoagulant prophylaxis for VTE. 13 Total knee arthroplasty has undergone significant changes in the last decade, resulting in a reduced VTE risk not accounted for in the current guidelines. 14, 15 The purpose of this study is to determine whether aspirin as a single agent is inferior to other anticoagulation agents for reducing the risk of VTE or major bleeding events after unilateral primary TKA.
Methods

Study Population
Background information on the Michigan Arthroplasty Registry Collaborative Quality Initiative (MARCQI), data sources, and variables collected have been previously described. 16 This is a multihospital consortium through which all elective primary total hip and knee arthroplasties at participating sites are entered into a registry with clinical laboratory values and preoperative, perioperative, and postoperative information. Trained clinical medical record abstractors follow up each case for 90 days after surgery using available data sources, such as hospital medical records and surgeon office notes. The Michigan Inpatient Data Base of the Michigan Hospital Association is used to obtain supplemental information for diagnoses and events occurring at the index hospital, as well as at external hospitals over time. Patients who left the state of Michigan would be lost to follow-up, but because all cases were manually abstracted out to 90 days, this is likely to be a rare scenario. This study population was a retrospective cohort of 49 221 consecutive primary unilateral total knee arthroplasty cases performed at MARCQI=participating hospitals between April 1, 2013, and October 31, 2015. Each case was followed up for 90 days after the day of surgery, making the latest date for follow-up January 28, 2016. For patients with multiple surgeries recorded in the registry, only the first surgery was included, excluding 4789 subsequent surgeries. The final data set contained information on 41 537 cases after excluding those in which the patient was taking anticoagulants on a daily basis within 30 days prior to surgery (2813 cases), anticoagulation started after a VTE event (26 cases), the only prophylaxis used began on or after postoperative day 2 (51 cases), or no recorded information regarding the presence or absence of VTE prophylaxis (5 cases) ( Figure 1) .
The MARCQI member hospitals were advised to follow the AAOS Guideline on Preventing Venous Thromboembolic Disease in Patients Undergoing Elective Hip and Knee Arthroplasty 4 that included aspirin for prophylaxis and recommend screening for VTE risk. At MARCQI quarterly meetings, clinicians were encouraged to use regional anesthesia, tranexamic acid, intermittent pneumatic compression devices, and early mobilization.
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Institutional review board review was obtained from the St Joseph Mercy Health System institutional review board, and the study was deemed to be exempt on July 2, 2014. For this reason, patient consent was not obtained. The original study protocol, dated June 15, 2014, proposed a study population that included both hip and knee arthroplasties. A power analysis with the number of cases available at that time showed that there was not adequate power. A second power analysis, conducted on October 2, 2014, based on a noninferiority analysis, assuming a baseline event rate of 1.0% and a noninferiority margin of .50, showed a power of 54% and indicated there were still too few cases in the registry at that time. Because a sufficient number of additional knee cases but not hip cases could be accrued over the subsequent 12 to 18 months, the study team narrowed the study to knee cases only and deferred analysis until adequate cases were accrued. Before the final analysis was conducted, there was a change in the study personnel that led to meetings to clarify the study question and appropriate statistical approach beginning September 2016.
The final power analysis was performed October 7, 2016, and found that 41 000 cases would be needed to reach 80%
Key Points
Question Is aspirin alone inferior to other anticoagulant medications for reducing the risk of venous thromboembolism (VTE) in patients after total knee arthroplasty?
Findings In this cohort study, 573 of 41 537 patients after total knee arthroplasty sustained a VTE event. Of those receiving prophylaxis, 541 had a VTE event; 149 if receiving aspirin alone, 321 when prescribed anticoagulation alone, and 71 if prescribed both aspirin and anticoagulation.
Meaning Aspirin alone may be an appropriate alternative to other pharmacologic prophylaxis in preventing VTE for patients undergoing total knee arthroplasty.
power using a noninferiority margin of 0. 
Main Outcomes
The primary composite outcome was the first occurrence of pulmonary embolism, deep venous thrombosis, or death during the 90-day postoperative period as determined by trained nurse abstractors. To avoid including superficial clots that were not clinically significant, a VTE event required a documented diagnosis, a confirmatory study, and treatment. Information as to location of the VTE and whether it was symptomatic was not recorded.
The secondary outcome was the occurrence of a major bleeding event within 90 days of surgery, excluding those that could be attributed to therapeutic anticoagulation for a VTE event. The date of the bleeding event was therefore part of the definition. For patients having a VTE event during the index hospitalization, a bleeding event was defined as a drop in hemoglobin of 7 g/dL or more (to convert to grams per liter, multiply by 10), a hematoma that occurred prior to the VTE, or a bleeding diagnosis recorded in the Michigan Inpatient Data Base that was not present on admission. For patients whose VTE occurred after the index hospitalization, the definition of bleeding was similar except that bleeding-related diagnoses recorded on readmissions identified in the Michigan Inpatient Data Base were required to be deemed present on admission. For patients not having a VTE during the 90 days of follow-up, the first occurrence of any of the aforementioned events was considered a major bleeding event.
Exposure
The exposure variable was the choice of agents for VTE prophylaxis initiated during the 3-day perioperative window (1 day To minimize the loss of power and decrease bias owing to exclusion of cases that were missing 1 or more covariates, missing covariates were imputed 10 times using multivariate sequential regression approach in SAS. The final analysis controlled for numerous patient, surgical, and hospital-level variables through inverse probability of treatment weighting. With this approach, cases in which the choice of prophylaxis appears statistically to have been heavily influenced by the risk factors considered are given less weight in the final analysis than cases for which the choice of strategy appears more random. Consequently, the analysis produces results that are less confounded, although never definitive and always subject to critical appraisal. Details are provided in the eMethods in the Supplement. The weights were derived from multinomial regression that accounted for differences in the prophylactic regimens based on differences in age; sex; race/ethnicity; body mass index; Elixhauser comorbidity diagnoses 20 ; preoperative values of hemoglobin, platelets, and creatinine; smoking history; preoperative treatment with antiplatelet agents; steroids and narcotics; preoperative history of venous thromboembolic disease; history of bleeding disorders; preoperative use of a cane or walker; American Society of Anesthesiologists status; marital status; type of insurance; surgical approach; operative duration; intermittent pneumatic compression devices; foot pumps; tranexamic acid; and anesthesia type (general or other). 21-23 Race/ethnicity was included owing to the relative increase risk of VTE in African American individuals 24 and was recorded by the clinical site abstractors as recorded in the hospital medical records. The hospital's frequency of screening for VTE was also included in the risk adjustment, calculated as the total number of venous ultrasonography examinations performed postoperatively divided by the number of cases performed at the hospital. 25 Hierarchical logistic regression models were used for the primary VTE and for the secondary bleeding analyses, weighted by the standardized inverse probability of treatment weights. The hierarchical nature of the data in the outcome model was evaluated by including a random effect for surgeon. 26 To test how the trajectories of composite VTE and bleeding events changed from 2013 to 2015, logistic regression models were fitted using 11 quarterly data points for the 2 outcomes separately. The β coefficients (standard error and P value) were computed. The P value level of significance was .05, and all P values were 2-sided. Finally, a sensitivity analysis was performed excluding patients with a history of VTE from the data set and then refitting all models with an updated inverse probability of treatment weighting. Odds ratios and P values were recalculated.
Results
There were 49 221 TKA cases in the database, and 41 537 met inclusion criteria ( Figure 1 ). The surgeries were performed in 29 hospitals by 374 surgeons. Six hundred sixty-eight patients (1.6%) were not receiving any pharmacologic VTE prophylaxis, 12 831 patients (30.9%) were receiving aspirin only, 22 620 (54.5%) were receiving at least 1 of 5 nonaspirin chemoprophylactic agents, and 5418 (13.0%) were receiving both aspirin and nonaspirin prophylaxis. Unadjusted, baseline patient demographics and characteristics are detailed in Table 1 .
Additional information on the study population is provided in eTables 1 and 2 the Supplement. A VTE event occurred in 1.38% of patients (573 of 41 537). Of the 668 patients receiving no pharmacologic prophylaxis, 4.79% (n = 32 of 668) had a composite VTE event; 2.40%, had a deep venous thromboembolism (n = 16 of 668), 1.95% had a PE (n = 13 of 668), and there were 3 deaths (0.45%). The rates of the composite VTE outcome and the components of death, pulmonary embolism, and deep venous thrombosis for the other regimens are shown in Multivariable analyses of the primary outcome reflecting adjustment for confounding showed that the patients receiving no prophylaxis had a several-fold higher risk than those given prophylaxis (adjusted OR, 5.13; 95% CI, 3.74-7.02). Patients taking aspirin only compared with other chemoprophylactic regimens had a noninferior risk of the composite VTE outcome, with an adjusted OR of 0.85 (95% CI, 0.68-1.07; P for inferiority = .007).
Overall, 1.10% of patients had the secondary outcome of bleeding (n = 457 of 41 537). In the 668 without prophylaxis, 1.50% had a bleeding event (n = 10 of 668). In the aspirin group, 0.90% (n = 116 of 12 831) had bleeding events. Bleeding occurred in 1.14% (n = 258 of 22 620) with anticoagulation and 1.35% (n = 73 of 5418) with both. After adjustment, aspirin was not inferior in the risk for a bleeding event when compared with other chemoprophylaxis (adjusted OR, 0.80; 95% CI, 0.63-1.00; P for inferiority <.001) ( Table 3 ). The findings were similar in the sensitivity analysis in which patients with a history of VTE were excluded (eAppendix in the Supplement).
During the study period, the use of chemoprophylaxis other than aspirin, including patients receiving both, decreased from 87.4% (n = 1847) to 47.9% (n = 877) of patients, whereas aspirin use rose from 10.2% (n = 215) to 50.0% (n = 915) ( Figure 2 ). There was no rise in the rate of VTE events (β = −0.02; SE = 0.01; P = .15), or bleeding events (β = −0.02; SE = 0.02; P = .21) during this time.
Discussion
In patients undergoing unilateral, primary TKA, aspirin alone was found to be noninferior to other forms of chemoprophylaxis in rates of VTE event or death, adjusting for confound- ers. These findings were supported by the stable incidence of composite VTE events despite a dramatic increase in the use of aspirin during the study period. The results emphasize the need for chemoprophylaxis vs no prophylaxis to reduce the risk of VTE, given the dramatically higher odds of a VTE in the group without prophylaxis. The registry data do not capture the reason 668 patients received no prophylaxis. The AAOS guidelines do recommend this approach along with intermittent pneumatic compression devices for patients at increased risk of sustaining a bleeding event but at standard risk for a VTE event. 4 This group had a 1.5% incidence of bleeding complication. However, the adjusted odds of bleeding were not significantly different for aspirin compared with anticoagulant or no prophylaxis vs anticoagulant.
There are several reasons to prefer using aspirin for VTE prophylaxis in the appropriately screened patient. Aspirin administration is simple, safe, and does not require monitoring. Although this study did not find a significant difference, a 2008 practice survey conducted by the American Association of Hip and Knee Surgeons found that while most orthopaedic surgeons felt LMWH to be most efficacious, aspirin was felt to be the easiest to use with the lowest risk of bleeding or wound complications. 27 Aspirin is also much less expensive. The reported cost for a 30-day supply of rivaroxaban is approximately $379 to $450, 28, 29 and that of LMWH is estimated at $450 to $890. 29, 30 Warfarin costs a few dollars for a 30-day course, but with monitoring considered, the cost approaches that of the other anticoagulants. 31 In contrast, aspirin costs approximately $2 per month, and no monitoring is needed. These cost differences could have a substantial association with a patient's out-of-pocket expenses as well as the cost of a hospital's overall bundle in the new episode payment models.
Limitations
The study has several limitations. First, the results may not apply to all settings outside of the MARCQI collaborative. Although this work represents the experience of a large number of patients and surgeons, it reflects an active, collaborative, quality improvement environment with motivated participants. Second, this is an observational study and can only demonstrate association and not causation. The analysis is limited by and dependent on the variables collected and the quality of the data. The surgeons chose aspirin or another method of anticoagulation based on their individual practice, determination of patient risk, and interpretation of the guidelines. Although measured potential confounders, including history of VTE, were addressed, it is not known to what extent the results were affected by unmeasured variables, such as intraoperative soft tissue handling or postoperative rehabilitation protocols. The conclusions of noninferiority were unchanged by the sensitivity analysis that excluded patients with history of VTE, but caution is needed when applying the results of this study to the treatment of patients with prior VTE. Third, we did not examine event rates for the specific agents included in the anticoagulation category. This was in part owing to the numerous combinations of agents used together as well as unknown information regarding the dosages used. Fourth, there are limitations with the definition of bleeding events. One could argue that a drop in hemoglobin level of 7 g/dL or greater is too stringent and could undercapture significant bleeding events. Also, the data collection protocol did not account for poten- 
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Research Original Investigation Aspirin vs Other Anticoagulants to Prevent Venous Thromboembolism After Total Knee Arthroplasty tial intra-articular bleeding that did not lead to a hospitalization, documentation of a hematoma, or a wound complication. Decreased local bleeding, swelling, and inflammation are difficult to track but may influence outcomes such as range of motion, function, and satisfaction. Future studies, including more standard definitions of bleeding events and the inclusion of patient-reported outcomes, may improve the validity of the events reported. Despite these limitations, further evidence to support the use of aspirin is provided by the stable incidence of VTE during the study period despite a dramatic rise in aspirin use (Figure 2 ). There is also increasing evidence in the literature for low rates of VTE events with the use of aspirin. While this observational study supports the use of aspirin, clinical judgment is still required for the ultimate selection of prophylaxis. In addition, only the pharmacologic prophylaxis was studied. This is just 1 component of a modern protocol that should also include regional anesthesia, comprehensive pain management protocols, intermittent pneumatic compression devices, tranexamic acid, and early mobilization. The expanded use of aspirin alone and the clarification of guidelines have the potential to simplify the care of these patients by surgeons, hospitalists, and primary care physicians and significantly reduce the cost of the episode of care without increasing the risk of VTE events.
Conclusions
Among patients undergoing TKA, aspirin was not inferior to other anticoagulants in the postoperative rate of VTE or death. Aspirin alone may provide similar protection from postoperative VTE compared with other anticoagulation treatments. Further prospective studies are needed to confirm these findings. Venous thromboembolism (VTE) is a recognized risk after total knee arthroplasty (TKA). 1 While nearly all orthopedic surgeons agree that pharmacologic prophylaxis is the standard of care, major disagreements remain about the optimal, or even acceptable, medication regimens. Even evidence-based guidelines from different national societies, 2,3 using the same published literature, often make different recommendations. 4 There has been a surge in aspirin use for VTE prophylaxis after TKA in the past decade; however, surgeons remain concerned about the safety and efficacy of this approach because of the limitations in studies supporting it. Two metaanalyses found low overall VTE rates with aspirin, but both also noted the low quality of studies and the variation in dosing regimens. 5 support for the use of aspirin, with some cautionary notes. As yet another retrospective cohort study, it is limited by the potential for selection bias and residual confounding. There is no standard by which pharmacologic prophylaxis was chosen, and numerous confounders influencing the choice cannot be included in the propensity score matching because they are not captured in the Michigan Arthroplasty Registry Collaborative Quality Initiative registry. There were significant differences in patient demographics (eg, body mass index, sex, race/ ethnicity, bleeding disorder, VTE history) and therapy provided (eg, surgical approach, anesthesia type, tranexamic acid, intermittent pneumatic compression devices) between the groups. The question remains unanswered of which specific selection criteria should be used to determine a recommen-
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For the analytical dataset 33,796 (81.36%) cases are complete without missing any value and 4,756 (11.45%) are missing only one data element resulting in 38,550 (92.81%) cases that are complete or only missing 1 value. The data point with the most missing values is creatinine with 7.2% missing, followed by assistive device usage at 4.2% missing.
The natural log transformation was applied to operation time and frequency of screening for VTE. Four variables, including age, BMI, pre-surgical hemoglobin and creatinine were centered at mean zero. Kruskal-Wallis Test is used to compare age , BMI, pre-surgical hemoglobin and creatinine and operation times between prophylaxis sub-groups (None, Anticoagulation Only, Aspirin Only, Both Anticoagulation and Aspirin). Chi-square test is used to test the association between categorical variables and prophylaxis sub-groups (None, Anticoagulation Only, Aspirin Only, Both Anticoagulation and Aspirin).
To minimize the loss of power and decrease bias due to exclusion of cases that were missing one or more covariates, missing covariates were imputed 10 times using multivariate sequential regression approach using SAS procedure proc MI and proc MIANALYZE. 1, 2 To minimize the potential for bias by indication between patient groups and to enhance causal inference, we derived inverse probability of treatment weights (IPTW) using multinomial logistic regression to determine the probability of patients being in each of four potential prophylactic regimen categories. [3] [4] [5] [6] The following explanatory variables were used to derive the probability of a given treatment: age, age 2 , BMI, BMI 2 , preoperative hemoglobin, preoperative creatinine, sex, ASA score, race, smoking status, insurance type, marital status, preoperative narcotic, steroid, or antiplatelet use, bleeding disorder, history of DVT or PE, use of assistive devices, Elixhauser comorbidities, foot pumps, tranexamic acid, general anesthesia, time period and VTE testing. Stabilized weights were calculated with consideration of marginal propensity score in each treatment group. To further account for overly influential cases (~1% of total cases), the stabilized weights were trimmed at 99 th percentiles, with weights beyond 99 th percentile replaced by the 99 th percentile value. [7] [8] [9] T-test was used to calculate the P values for inferiority.
10,11 Table 1 in the manuscript is a shortened version for the manuscript. Appendix Table A includes the complete list of unadjusted data elements.
Appendix Table B reports the results of a sensitivity analysis performed by excluding patients with a prior history of VTE, rebuilding the propensity score model and recalculating the OR and P values. While the absolute values of the OR (95%) and p values change slightly when excluding the 2320 cases with a history of VTE, the significance conclusion remains the same. This sensitivity analysis suggests that the fundamental conclusions of the non-inferiority of aspirin compared with other anticoagulants are still established, with p for inferiority = 0.0177 for VTE/PE and p for inferiority = 0.0085 for bleeding, respectively. 
